Want to see NOTVQ full AI Analyst Report?
NOTVQ Stock Chart & Stats
$0.54
-$0.86(-17.00%)
At close: 4:00 PM EST
$0.54
-$0.86(-17.00%)
Day’s Range― - ―
52-Week Range<$0.01 - $2.44
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.20M
Market Cap
$418.66K
Enterprise Value$482.56M
Total Cash (Recent Filing)$15.18M
Total Debt (Recent Filing)$487.77M
Price to Earnings (P/E)―
Beta1.99
Next Earnings
Aug 12, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.53
Shares Outstanding34,888,145
10 Day Avg. Volume429,089
30 Day Avg. Volume1,202,902
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.35
Price to Sales (P/S)0.09
P/FCF Ratio-1.74
Enterprise Value/Market Cap1.15K
Enterprise Value/Revenue0.95
Enterprise Value/Gross Profit6.47
Enterprise Value/Ebitda47.32
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.27
Revenue Forecast (FY)$529.53M
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAEBITDA exceeded expectations, indicating financial performance is stronger than anticipated.
Revenue GrowthDiscovery orders increased by 16%, marking the first growth in this area in two years, which is expected to drive overall growth.
Bears Say
Market DemandA material change in research model demand would impact Inotiv’s business.
NOTVQ FAQ
What was Inotiv’s price range in the past 12 months?
Inotiv lowest stock price was <$0.01 and its highest was $2.44 in the past 12 months.
What is Inotiv’s market cap?
Inotiv’s market cap is $418.66K.
When is Inotiv’s upcoming earnings report date?
Inotiv’s upcoming earnings report date is Aug 12, 2026 which is in 43 days.
How were Inotiv’s earnings last quarter?
Inotiv released its earnings results on May 07, 2026. The company reported -$0.937 earnings per share for the quarter, missing the consensus estimate of -$0.635 by -$0.302.
Is Inotiv overvalued?
According to Wall Street analysts Inotiv’s price is currently Overvalued.
Does Inotiv pay dividends?
Inotiv does not currently pay dividends.
What is Inotiv’s EPS estimate?
Inotiv’s EPS estimate is -0.06.
How many shares outstanding does Inotiv have?
Inotiv has 34,888,145 shares outstanding.
What happened to Inotiv’s price movement after its last earnings report?
Inotiv reported an EPS of -$0.937 in its last earnings report, missing expectations of -$0.635. Following the earnings report the stock price went down -1.672%.
Which hedge fund is a major shareholder of Inotiv?
Currently, no hedge funds are holding shares in NOTVQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Inotiv
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana. On June 3, 2026, Inotiv, Inc. along with its affiliates filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.
NOTVQ Earnings Call
Q1 2026
0:00 / 0:00
Technical Analysis
Ownership Overview
7.74% Insiders
2.45% Mutual Funds
2.87% Other Institutional Investors
85.98% Public Companies and
Individual Investors